• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
156916 162 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
7 {: B/ [0 E3 V/ `" h* H
可以,但要有针对性,
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  ) K% Y; @* N. ^4 W7 {

  H7 ^: @2 Z  _2 l2 `0 d- A( \! D# }/ d. n  b
Sub-category:$ K, o/ A/ k4 c4 M
Molecular Targets
; ?3 z2 U, V' U5 P
8 G2 A9 q" {8 ~1 Z! V8 e1 Q4 d  U- x9 N9 S
Category:
: ~. F1 |; r6 I9 [/ ]( W/ R) cTumor Biology
, D$ w5 S, p: k0 {- t: \6 t7 l' m; i/ {4 }& q! p! s( p" k; ?

* {- r: l) R, W6 W1 [Meeting:
$ a. l  `( n& Q# t* O2011 ASCO Annual Meeting ) x8 E2 g: ?. g8 ?( \
/ n4 }; {" w% z3 u  \5 |, Z  e7 \; _7 {

0 H) Q0 y3 @6 l" s  N- F7 B" sSession Type and Session Title:$ Y5 J) p# X8 d( J( H# _% k6 r- ]
Poster Discussion Session, Tumor Biology
; i  Q+ ^9 o4 H6 F0 S$ r, t) {6 u. ]: _) B
0 j% ^2 O. M  _/ G: Z3 j2 b; z
Abstract No:& w+ m" v; Z$ l" H
10517 4 Z1 [5 ?7 a/ u! G  g* t

& p0 F( ^; s) _4 A5 X
3 l: D# M+ l$ jCitation:1 r$ t; {. G. }9 t- _
J Clin Oncol 29: 2011 (suppl; abstr 10517)
$ L; k7 |  K, E. r) e: A
* J/ o: j" Y0 Q1 U2 n( S7 A4 a
9 t' L8 a0 @) u& f, o0 P4 @Author(s):  p  Q, h, a7 w) @# G
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
+ t2 R& L2 a: z# u9 N! U9 S8 P& V( D% P' j
5 `+ s. ?5 f6 B; \: G8 R' \
' \0 Z* Y$ E1 k" U" b
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.) c/ W8 @& i2 P; a9 c
" e, o" t; h2 U* ]3 j, m
Abstract Disclosures
7 }+ C; N6 _! z0 h7 x6 `4 t8 l3 N' u* x6 ], Y  F. H
Abstract:
4 q' @# t" e7 `7 Y$ o
  [4 p7 U/ e! Q1 V
) \0 @2 g1 q  {! FBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
% a; I6 L: T. Y* K7 `4 P; o: L  w2 _+ ]8 i" g

* J8 H$ T8 I) K+ a5 d: A- g5 o
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 1 F: w1 b1 ~/ K# K5 f
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

. u, ?5 V+ `5 ^* @化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 # k! d3 F& x- d) M- \2 }3 {
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。. v/ `8 ~/ \, _0 M, c* L
ALK一个指标医院要900多 ...

, P. S, [# g! Y! K, o3 ?平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?. Z3 x1 j! N: J. h" o

% B8 H# n! M- t# ^& w! J现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表